Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2013

Open Access 01-12-2013 | Research article

Overexpression of peptide deformylase in breast, colon, and lung cancers

Authors: Harsharan Randhawa, Shireen Chikara, Drew Gehring, Tuba Yildirim, Jyotsana Menon, Katie M Reindl

Published in: BMC Cancer | Issue 1/2013

Login to get access

Abstract

Background

Human mitochondrial peptide deformylase (PDF) has been proposed as a novel cancer therapeutic target. However, very little is known about its expression and regulation in human tissues. The purpose of this study was to characterize the expression pattern of PDF in cancerous tissues and to identify mechanisms that regulate its expression.

Methods

The mRNA expression levels of PDF and methionine aminopeptidase 1D (MAP1D), an enzyme involved in a related pathway with PDF, were determined using tissue panels containing cDNA from patients with various types of cancer (breast, colon, kidney, liver, lung, ovarian, prostate, or thyroid) and human cell lines. Protein levels of PDF were also determined in 2 colon cancer patients via western blotting. Colon cancer cells were treated with inhibitors of ERK, Akt, and mTOR signaling pathways and the resulting effects on PDF and MAP1D mRNA levels were determined by qPCR for colon and lung cancer cell lines. Finally, the effects of a PDF inhibitor, actinonin, on the proliferation of breast, colon, and prostate cell lines were determined using the CyQUANT assay.

Results

PDF and MAP1D mRNA levels were elevated in cancer cell lines compared to non-cancer lines. PDF mRNA levels were significantly increased in breast, colon, and lung cancer samples while MAP1D mRNA levels were increased in just colon cancers. The expression of PDF and MAP1D varied with stage in these cancers. Further, PDF protein expression was elevated in colon cancer tissue samples. Inhibition of the MEK/ERK, but not PI3K or mTOR, pathway reduced the expression of PDF and MAP1D in both colon and lung cancer cell lines. Further, inhibition of PDF with actinonin resulted in greater reduction of breast, colon, and prostate cancer cell proliferation than non-cancer cell lines.

Conclusions

This is the first report showing that PDF is over-expressed in breast, colon, and lung cancers, and the first evidence that the MEK/ERK pathway plays a role in regulating the expression of PDF and MAP1D. The over-expression of PDF in several cancers and the inhibition of cancer cell growth by a PDF inhibitor suggest this enzyme may act as an oncogene to promote cancer cell proliferation.
Appendix
Available only for authorised users
Literature
1.
Solbiati J, Chapman-Smith A, Miller JL, Miller CG, Cronan JE: Processing of the N termini of nascent polypeptide chains requires deformylation prior to methionine removal. J Mol Biol. 1999, 290 (3): 607-614. 10.1006/jmbi.1999.2913.CrossRefPubMed
2.
Nguyen KT, Hu X, Colton C, Chakrabarti R, Zhu MX, Pei D: Characterization of a human peptide deformylase: implications for antibacterial drug design. Biochemistry. 2003, 42 (33): 9952-9958. 10.1021/bi0346446.CrossRefPubMed
3.
Giglione C, Meinnel T: Peptide deformylase as an emerging target for antiparasitic agents. Expert Opin Ther Targets. 2001, 5 (1): 41-57. 10.1517/14728222.5.1.41.PubMed
4.
Giglione C, Pierre M, Meinnel T: Peptide deformylase as a target for new generation, broad spectrum antimicrobial agents. Mol Microbiol. 2000, 36 (6): 1197-1205.CrossRefPubMed
5.
Leeds JA, Dean CR: Peptide deformylase as an antibacterial target: a critical assessment. Curr Opin Pharmacol. 2006, 6 (5): 445-452. 10.1016/j.coph.2006.06.003.CrossRefPubMed
6.
Giglione C, Serero A, Pierre M, Boisson B, Meinnel T: Identification of eukaryotic peptide deformylases reveals universality of N-terminal protein processing mechanisms. EMBO J. 2000, 19 (21): 5916-5929. 10.1093/emboj/19.21.5916.CrossRefPubMedPubMedCentral
7.
Serero A, Giglione C, Meinnel T: Distinctive features of the two classes of eukaryotic peptide deformylases. J Mol Biol. 2001, 314 (4): 695-708. 10.1006/jmbi.2001.5175.CrossRefPubMed
8.
Serero A, Giglione C, Sardini A, Martinez-Sanz J, Meinnel T: An unusual peptide deformylase features in the human mitochondrial N-terminal methionine excision pathway. J Biol Chem. 2003, 278 (52): 52953-52963. 10.1074/jbc.M309770200.CrossRefPubMed
9.
Lee MD, Antczak C, Li Y, Sirotnak FM, Bornmann WG, Scheinberg DA: A new human peptide deformylase inhibitable by actinonin. Biochem Biophys Res Commun. 2003, 312 (2): 309-315. 10.1016/j.bbrc.2003.10.123.CrossRefPubMed
10.
Carroll J, Fearnley IM, Walker JE: Definition of the mitochondrial proteome by measurement of molecular masses of membrane proteins. Proc Natl Acad Sci USA. 2006, 103 (44): 16170-16175. 10.1073/pnas.0607719103.CrossRefPubMedPubMedCentral
11.
Escobar-Alvarez S, Gardner J, Sheth A, Manfredi G, Yang G, Ouerfelli O, Heaney ML, Scheinberg DA: Inhibition of human peptide deformylase disrupts mitochondrial function. Mol Cell Biol. 2010, 30 (21): 5099-5109. 10.1128/MCB.00469-10.CrossRefPubMedPubMedCentral
12.
Leszczyniecka M, Bhatia U, Cueto M, Nirmala NR, Towbin H, Vattay A, Wang B, Zabludoff S, Phillips PE: MAP1D, a novel methionine aminopeptidase family member is overexpressed in colon cancer. Oncogene. 2006, 25 (24): 3471-3478. 10.1038/sj.onc.1209383.CrossRefPubMed
13.
Lee MD, She Y, Soskis MJ, Borella CP, Gardner JR, Hayes PA, Dy BM, Heaney ML, Philips MR, Bornmann WG, et al: Human mitochondrial peptide deformylase, a new anticancer target of actinonin-based antibiotics. J Clin Invest. 2004, 114 (8): 1107-1116.CrossRefPubMedPubMedCentral
14.
Antczak C, Shum D, Bassit B, Frattini MG, Li Y, Stanchina E, Scheinberg DA, Djaballah H: Identification of benzofuran-4,5-diones as novel and selective non-hydroxamic acid, non-peptidomimetic based inhibitors of human peptide deformylase. Bioorg Med Chem Lett. 2011, 21 (15): 4528-4532. 10.1016/j.bmcl.2011.05.129.CrossRefPubMedPubMedCentral
15.
Antczak C, Shum D, Escobar S, Bassit B, Kim E, Seshan VE, Wu N, Yang G, Ouerfelli O, Li YM, et al: High-throughput identification of inhibitors of human mitochondrial peptide deformylase. J Biomol Screen. 2007, 12 (4): 521-535. 10.1177/1087057107300463.CrossRefPubMedPubMedCentral
16.
Escobar-Alvarez S, Goldgur Y, Yang G, Ouerfelli O, Li Y, Scheinberg DA: Structure and activity of human mitochondrial peptide deformylase, a novel cancer target. J Mol Biol. 2009, 387 (5): 1211-1228. 10.1016/j.jmb.2009.02.032.CrossRefPubMedPubMedCentral
Metadata
Title
Overexpression of peptide deformylase in breast, colon, and lung cancers
Authors
Harsharan Randhawa
Shireen Chikara
Drew Gehring
Tuba Yildirim
Jyotsana Menon
Katie M Reindl
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2013
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-13-321

Other articles of this Issue 1/2013

BMC Cancer 1/2013 Go to the issue

Research article

Antioxidant-mediated up-regulation of OGG1 via NRF2 induction is associated with inhibition of oxidative DNA damage in estrogen-induced breast cancer

Research article

Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker

Research article

HOXB7 mRNA is overexpressed in pancreatic ductal adenocarcinomas and its knockdown induces cell cycle arrest and apoptosis

Research article

CD133 expression is not an independent prognostic factor in stage II and III colorectal cancer but may predict the better outcome in patients with adjuvant therapy

Research article

Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma

Research article

Expression and DNA methylation levels of prolyl hydroxylases PHD1, PHD2, PHD3 and asparaginyl hydroxylase FIH in colorectal cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits